MCID: CRB138
MIFTS: 43

Core Binding Factor Acute Myeloid Leukemia

Categories: Blood diseases, Cancer diseases

Aliases & Classifications for Core Binding Factor Acute Myeloid Leukemia

MalaCards integrated aliases for Core Binding Factor Acute Myeloid Leukemia:

Name: Core Binding Factor Acute Myeloid Leukemia 25 17 72
Cbf Acute Myeloid Leukemia 25
Core-Binding Factor Aml 25
Cbf-Aml 25

Classifications:



External Ids:

UMLS 72 C3839741

Summaries for Core Binding Factor Acute Myeloid Leukemia

Genetics Home Reference : 25 Core binding factor acute myeloid leukemia (CBF-AML) is one form of a cancer of the blood-forming tissue (bone marrow) called acute myeloid leukemia. In normal bone marrow, early blood cells called hematopoietic stem cells develop into several types of blood cells: white blood cells (leukocytes) that protect the body from infection, red blood cells (erythrocytes) that carry oxygen, and blood cell fragments called platelets (thrombocytes) that are involved in blood clotting. In acute myeloid leukemia, the bone marrow makes large numbers of abnormal, immature white blood cells called myeloid blasts. Instead of developing into normal white blood cells, the myeloid blasts develop into cancerous leukemia cells. The large number of abnormal cells in the bone marrow interferes with the production of functional white blood cells, red blood cells, and platelets. People with CBF-AML have a shortage of all types of mature blood cells: a shortage of white blood cells (leukopenia) leads to increased susceptibility to infections, a low number of red blood cells (anemia) causes fatigue and weakness, and a reduction in the amount of platelets (thrombocytopenia) can result in easy bruising and abnormal bleeding. Other symptoms of CBF-AML may include fever and weight loss. While acute myeloid leukemia is generally a disease of older adults, CBF-AML often begins in young adulthood and can occur in childhood. Compared to other forms of acute myeloid leukemia, CBF-AML has a relatively good prognosis: about 90 percent of individuals with CBF-AML recover from their disease following treatment, compared with 25 to 40 percent of those with other forms of acute myeloid leukemia. However, the disease recurs in approximately half of them after successful treatment of the initial occurrence.

MalaCards based summary : Core Binding Factor Acute Myeloid Leukemia, also known as cbf acute myeloid leukemia, is related to cytogenetically normal acute myeloid leukemia and sarcoma. An important gene associated with Core Binding Factor Acute Myeloid Leukemia is KIT (KIT Proto-Oncogene, Receptor Tyrosine Kinase), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Fludarabine and Vidarabine have been mentioned in the context of this disorder. Affiliated tissues include myeloid, bone and bone marrow, and related phenotypes are Decreased viability and Decreased viability

Related Diseases for Core Binding Factor Acute Myeloid Leukemia

Diseases related to Core Binding Factor Acute Myeloid Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 89)
# Related Disease Score Top Affiliating Genes
1 cytogenetically normal acute myeloid leukemia 30.4 WT1 FLT3 CEBPA
2 sarcoma 30.1 WT1 KRAS KIT HRAS
3 leukemia 29.7 WT1 RUNX1 NRAS KIT JAK2 FLT3
4 myeloid leukemia 29.3 WT1 RUNX1 NRAS KIT JAK2 HRAS
5 acute leukemia 28.8 WT1 RUNX1 KIT JAK2 FLT3 CSF3
6 leukemia, acute myeloid 26.6 WT1 RUNX2 RUNX1 NRAS KRAS KIT
7 myelodysplastic syndrome 26.5 WT1 RUNX1 NRAS KRAS KIT JAK2
8 acute myeloblastic leukemia with maturation 10.7 KIT FLT3
9 thymoma, familial 10.6 KIT HRAS
10 sigmoid neoplasm 10.6 KRAS HRAS
11 subacute myeloid leukemia 10.6 JAK2 FLT3
12 uterine inversion 10.5 KIT CSF1R
13 apocrine adenoma 10.5 KRAS HRAS
14 8p11 myeloproliferative syndrome 10.5 RUNX1 KIT FLT3
15 paronychia 10.5 KRAS HRAS
16 periampullary adenoma 10.5 KRAS HRAS
17 bile duct cysts 10.4 KRAS HRAS
18 testicular gonadoblastoma 10.4 WT1 KIT
19 aggressive digital papillary adenocarcinoma 10.4 KRAS KIT HRAS
20 giant congenital nevus 10.4 NRAS HRAS
21 lung adenoid cystic carcinoma 10.4 KRAS KIT HRAS
22 acute erythroid leukemia 10.4 JAK2 CEBPA
23 conventional fibrosarcoma 10.4 NRAS KIT
24 appendix disease 10.4 KRAS HRAS
25 carcinosarcoma 10.4 KRAS KIT HRAS
26 acral lentiginous melanoma 10.4 NRAS KIT
27 benign struma ovarii 10.4 NRAS HRAS
28 hematopoietic stem cell transplantation 10.3
29 gastrointestinal system cancer 10.3 KRAS KIT HRAS
30 malignant spindle cell melanoma 10.3 NRAS KIT
31 malignant conjunctival melanoma 10.3 NRAS HRAS
32 gastrointestinal system disease 10.3 KRAS KIT HRAS
33 ovarian melanoma 10.3 NRAS KIT HRAS
34 chronic eosinophilic leukemia 10.3 WT1 KIT FLT3
35 acute myeloid leukemia with t(8;21)(q22;q22) translocation 10.3 RUNX1 KIT FLT3 CEBPA
36 vulvar melanoma 10.2 NRAS KIT HRAS
37 malignant skin fibrous histiocytoma 10.2 NRAS KIT HRAS
38 schimmelpenning-feuerstein-mims syndrome 10.2 NRAS KRAS HRAS
39 malignant dermis tumor 10.2 NRAS KIT HRAS
40 chromosomal triplication 10.2
41 trisomy 22 10.2
42 central nervous system melanocytic neoplasm 10.2 NRAS KIT HRAS
43 acneiform dermatitis 10.2 NRAS KRAS HRAS
44 diffuse peritoneal leiomyomatosis 10.2 WT1 KIT
45 liver angiosarcoma 10.2 NRAS KRAS HRAS
46 nevus, epidermal 10.2 NRAS KRAS HRAS
47 chronic myelomonocytic leukemia 10.2 RUNX1 KIT JAK2 FLT3
48 leukemia, chronic lymphocytic 2 10.2 NRAS KRAS HRAS
49 peritoneal benign neoplasm 10.2 WT1 KIT
50 differentiated thyroid carcinoma 10.2 NRAS KRAS HRAS

Graphical network of the top 20 diseases related to Core Binding Factor Acute Myeloid Leukemia:



Diseases related to Core Binding Factor Acute Myeloid Leukemia

Symptoms & Phenotypes for Core Binding Factor Acute Myeloid Leukemia

GenomeRNAi Phenotypes related to Core Binding Factor Acute Myeloid Leukemia according to GeneCards Suite gene sharing:

26 (show all 12)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.25 HRAS KRAS
2 Decreased viability GR00106-A-0 10.25 KRAS
3 Decreased viability GR00173-A 10.25 FLT3
4 Decreased viability GR00221-A-1 10.25 CSF1R FLT3 HRAS KIT KRAS NRAS
5 Decreased viability GR00221-A-2 10.25 HRAS KRAS
6 Decreased viability GR00221-A-3 10.25 HRAS NRAS
7 Decreased viability GR00221-A-4 10.25 CSF1R FLT3
8 Decreased viability GR00301-A 10.25 KIT KRAS
9 Decreased viability GR00381-A-1 10.25 KRAS
10 Decreased viability GR00402-S-2 10.25 CSF1R FLT3 HRAS KIT KRAS NRAS
11 Increased cell migration GR00055-A-3 9.26 CBL CSF1R HRAS KRAS
12 Reduced mammosphere formation GR00396-S 9.23 CEBPA CSF1R CSF3 HRAS KRAS NRAS

MGI Mouse Phenotypes related to Core Binding Factor Acute Myeloid Leukemia:

46 (show all 20)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.4 ABCG2 CBFB CBL CEBPA CSF1R FLT3
2 hematopoietic system MP:0005397 10.38 ABCG2 CBFB CBL CEBPA CSF1R CSF3
3 endocrine/exocrine gland MP:0005379 10.37 CBFB CBL CEBPA CSF1R FLT3 HRAS
4 homeostasis/metabolism MP:0005376 10.37 ABCG2 CBFB CBL CEBPA CSF1R FLT3
5 growth/size/body region MP:0005378 10.36 CBFB CBL CEBPA CSF1R FLT3 HRAS
6 immune system MP:0005387 10.36 ABCG2 CBFB CBL CEBPA CSF1R CSF3
7 integument MP:0010771 10.31 ABCG2 CBFB CBL CEBPA CSF1R CSF3
8 cardiovascular system MP:0005385 10.29 CBFB CBL CEBPA HRAS KIT KRAS
9 mortality/aging MP:0010768 10.25 CBFB CBL CEBPA CSF1R FLT3 HRAS
10 liver/biliary system MP:0005370 10.2 ABCG2 CBFB CBL CEBPA JAK2 KIT
11 craniofacial MP:0005382 10.18 CBFB CBL CSF1R HRAS KIT KRAS
12 digestive/alimentary MP:0005381 10.11 CBFB CEBPA HRAS KIT KRAS NRAS
13 no phenotypic analysis MP:0003012 10.11 CBFB CEBPA CSF1R FLT3 HRAS KIT
14 neoplasm MP:0002006 10.1 CBFB CEBPA FLT3 HRAS JAK2 KIT
15 normal MP:0002873 10.1 ABCG2 CBFB CEBPA CSF1R HRAS JAK2
16 limbs/digits/tail MP:0005371 10.02 CBFB CBL CSF1R KIT KRAS NRAS
17 renal/urinary system MP:0005367 9.8 ABCG2 CEBPA CSF3 HRAS KIT KRAS
18 reproductive system MP:0005389 9.76 CBL CEBPA CSF1R JAK2 KIT KRAS
19 respiratory system MP:0005388 9.61 CBFB CBL CEBPA HRAS KIT KRAS
20 skeleton MP:0005390 9.36 CBFB CBL CSF1R FLT3 HRAS JAK2

Drugs & Therapeutics for Core Binding Factor Acute Myeloid Leukemia

Drugs for Core Binding Factor Acute Myeloid Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 39)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fludarabine Approved Phase 4 21679-14-1, 75607-67-9 30751
2
Vidarabine Approved, Investigational Phase 4 24356-66-9 21704 32326
3
Sargramostim Approved, Investigational Phase 2 83869-56-1, 123774-72-1
4
Mitoxantrone Approved, Investigational Phase 2 65271-80-9 4212
5
Etoposide Approved Phase 2 33419-42-0 36462
6
Lenograstim Approved, Investigational Phase 2 135968-09-1
7
Busulfan Approved, Investigational Phase 2 55-98-1 2478
8
Azacitidine Approved, Investigational Phase 2 320-67-2 9444
9
Decitabine Approved, Investigational Phase 2 2353-33-5 451668
10
midostaurin Approved, Investigational Phase 2 120685-11-2 104937 9829523
11
Dasatinib Approved, Investigational Phase 2 302962-49-8 3062316
12
Daunorubicin Approved Phase 2 20830-81-3 30323
13
Cytarabine Approved, Experimental, Investigational Phase 2 147-94-4, 65-46-3 6253
14
Alvocidib Experimental, Investigational Phase 2 146426-40-6, 131740-09-5 5287969
15 Staurosporine Experimental Phase 2 62996-74-1
16 Analgesics Phase 2
17 Antineoplastic Agents, Phytogenic Phase 2
18 Adjuvants, Immunologic Phase 2
19 Peripheral Nervous System Agents Phase 2
20 Etoposide phosphate Phase 2
21 Tubulin Modulators Phase 2
22 Alkylating Agents Phase 2
23 Keratolytic Agents Phase 2
24 Dermatologic Agents Phase 2
25 Podophyllotoxin Phase 2 518-28-5
26 Antimitotic Agents Phase 2
27 Antineoplastic Agents, Alkylating Phase 2
28 Anti-Infective Agents Phase 2
29 Protein Kinase Inhibitors Phase 2
30 Anti-Bacterial Agents Phase 2
31 Immunosuppressive Agents Phase 2
32 Antibiotics, Antitubercular Phase 2
33 Topoisomerase Inhibitors Phase 2
34 Antimetabolites Phase 2
35 Antimetabolites, Antineoplastic Phase 2
36 Antiviral Agents Phase 2
37 Immunologic Factors Phase 2
38
Vitamin C Approved, Nutraceutical 50-81-7 54670067 5785
39 Aclacinomycins

Interventional clinical trials:

(show all 14)
# Name Status NCT ID Phase Drugs
1 Fludarabine and Cytarabine Versus High-dose Cytarabine in Consolidation Treatment of Core-bing Factor Acute Myeloid Leukemia: A Prospective, Multicenter, Randomized Study Recruiting NCT02926586 Phase 4 Fludarabine;Cytarabine
2 A Phase 3 Trial of Systematic Versus Response-adapted Timed-Sequential Induction in Patients With Core Binding Factor (CBF) Acute Myeloid Leukemia (AML) Completed NCT00428558 Phase 3 Chemotherapy (DAUNORUBICINE-CYTARABINE);Chemotherapy (DAUNORUBICINE-CYTARABINE)
3 Randomized Phase III Study of Intensive Chemotherapy With or Without Dasatinib (Sprycel™) in Adult Patients With Newly Diagnosed Core-Binding Factor Acute Myeloid Leukemia (CBF-AML) Recruiting NCT02013648 Phase 3 Dasatinib;Cytarabine;Daunorubicin
4 Open-Label, Multicenter Phase Ib/IIa Study For the Evaluation of Dasatinib (Sprycel™) Following Induction and Consolida-tion Therapy as Well as in Maintenance Therapy in Patients With Newly Diagnosed Core Binding Factor (CBF) Acute Myeloid Leukemia (AML) Completed NCT00850382 Phase 1, Phase 2 Dasatinib;daunorubicin;Cytarabine
5 Phase II Study of Alvocidib (NSC 649890, Flavopiridol) in Timed Sequential Combination With Cytosine Arabinoside (Ara-C) and Mitoxantrone for Adults With Newly Diagnosed, Previously Untreated, Poor-Risk Acute Myelogenous Leukemias Completed NCT00407966 Phase 2 alvocidib;cytarabine;mitoxantrone hydrochloride
6 Phase II Study of Maintenance Therapy With Decitabine (NSC #127716) Following Standard Induction and Cytogenetic Risk-Adapted Intensification in Previously Untreated Patients With AML < 60 Years Completed NCT00416598 Phase 2 Busulfan;Cytarabine;Daunorubicin Hydrochloride;Decitabine;Etoposide
7 Prospective Evaluation of a Continuation Therapy With Midostaurin in Adult Patients With Core-binding Factor Leukemia and Integrated Genetic Analysis: a Multi-center Phase II Study Recruiting NCT03686345 Phase 2 Midostaurin
8 Efficacy and Safety of Chidamide in CBF Leukemia Recruiting NCT03031262 Phase 1, Phase 2 Cytarabine;Chidamide
9 A Phase II Study of Induction (Daunorubicin/Cytarabine) and Consolidation (High-Dose Cytarabine) Chemotherapy Plus Dasatinib (NSC #732517) and Continuation Therapy With Dasatinib Alone in Newly Diagnosed Patients With Core Binding Factor Acute Myeloid Leukemia (AML) Active, not recruiting NCT01238211 Phase 2 Cytarabine;Dasatinib;Daunorubicin Hydrochloride
10 Cytarabine Plus Continuous Infusion Daunorubicin Induction Therapy for Adults With Acute Myeloid Leukemia: A Feasibility Study With Cardiac MRI Monitoring Active, not recruiting NCT02971397 Phase 2 Cytarabine;Daunorubicin Hydrochloride
11 Dasatinib in Combination With Chemotherapy for Relapsed or Refractory Core Binding Factor Acute Myeloid Leukemia: A Phase I Study (AflacLL1401) Withdrawn NCT02680951 Phase 1 Dasatinib;Fludarabine;Cytarabine;Idarubicin;Intrathecal (IT) cytarabine
12 Genome Wide SNP Array-based Approach to Detect Micro-cytogenetic Lesions and KIT Mutation to Improve Treatment Outcomes in Patients With Core-binding Factor Positive Acute Myeloid Leukemia Unknown status NCT01066286
13 The Efficiency of CAMS-2016 Trial for the Newly Diagnosed Pediatric Acute Myeloid Leukemia: A Prospective Single Centre Trial From China Recruiting NCT03173612 Dasatinib
14 Phase 2 Study of Autologous Hematopoietic Cell Transplantation for Core-binding Factor Positive Acute Myeloid Leukemia in the First Complete Remission Recruiting NCT01050036

Search NIH Clinical Center for Core Binding Factor Acute Myeloid Leukemia

Genetic Tests for Core Binding Factor Acute Myeloid Leukemia

Anatomical Context for Core Binding Factor Acute Myeloid Leukemia

MalaCards organs/tissues related to Core Binding Factor Acute Myeloid Leukemia:

41
Myeloid, Bone, Bone Marrow, Eye

Publications for Core Binding Factor Acute Myeloid Leukemia

Articles related to Core Binding Factor Acute Myeloid Leukemia:

(show top 50) (show all 132)
# Title Authors PMID Year
1
[Characterization of mutational pattern of patients with core-binding factor acute myeloid leukemia]. 38
31302905 2019
2
Oncogenic KIT mutations induce STAT3-dependent autophagy to support cell proliferation in acute myeloid leukemia. 38
31311917 2019
3
Myeloid translocation gene CBFA2T3 directs a relapse gene program and determines patient-specific outcomes in AML. 38
31040112 2019
4
Different prognostic effects of core-binding factor positive AML with Korean AML registry data. 38
30758645 2019
5
The stem cell-associated gene expression signature allows risk stratification in pediatric acute myeloid leukemia. 38
30089916 2019
6
[Study of clinical outcome and prognosis in pediatric core binding factor-acute myeloid leukemia]. 38
30704229 2019
7
Inhibition of N822K T>A mutation-induced constitutive c-KIT activation in AML cells triggers apoptotic and autophagic pathways leading to death. 38
31217744 2019
8
Wilms Tumor 1 Expression at Diagnosis Correlates With Genetic Abnormalities and Polymorphism But Is Not Independently Prognostic in Acute Myelogenous Leukemia: A Hokkaido Leukemia Net Study. 38
30082223 2018
9
Core-binding factor acute myeloid leukemia with t(8;21): Risk factors and a novel scoring system (I-CBFit). 38
30117318 2018
10
Ten-year outcome of patients with acute myeloid leukemia not treated with allogeneic transplantation in first complete remission. 38
29991495 2018
11
Adding dasatinib to intensive treatment in core-binding factor acute myeloid leukemia-results of the AMLSG 11-08 trial. 38
29720733 2018
12
Clonal interference of signaling mutations worsens prognosis in core-binding factor acute myeloid leukemia. 38
29692343 2018
13
Evolution of a chemosensitive core-binding factor AML into an aggressive leukemia with eosinophilic differentiation. 38
29950292 2018
14
Monitoring of clonal evolution of double C-KIT exon 17 mutations by Droplet Digital PCR in patients with core-binding factor acute myeloid leukemia. 38
29705537 2018
15
Genome-wide genotype-based risk model for survival in core binding factor acute myeloid leukemia patients. 38
29500710 2018
16
Prognostic markers in core-binding factor AML and improved survival with multiple consolidation cycles of intermediate-/high-dose cytarabine. 38
29719925 2018
17
KIT mutations correlate with adverse survival in children with core-binding factor acute myeloid leukemia. 38
28792268 2018
18
Detection of KIT mutations in core binding factor acute myeloid leukemia. 38
30112273 2018
19
Outcomes of Patients With Relapsed Core Binding Factor-Positive Acute Myeloid Leukemia. 38
29107583 2018
20
[Molecular pathogenesis and treatment of core binding factor-acute myeloid leukemia]. 38
30305502 2018
21
SNP-array lesions in core binding factor acute myeloid leukemia. 38
29464086 2018
22
Predictive value of molecular remissions postconsolidation chemotherapy in patients with Core Binding Factor Acute Myeloid Leukemia (CBF-AML) - a single center analysis. 38
27597292 2017
23
Outcome of relapsed core binding factor acute myeloid leukemia in children: A result from the Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG) AML-05R study. 38
28233452 2017
24
D816 mutation of the KIT gene in core binding factor acute myeloid leukemia is associated with poorer prognosis than other KIT gene mutations. 38
28762080 2017
25
Factors associated with risk of central nervous system relapse in patients with non-core binding factor acute myeloid leukemia. 38
28556489 2017
26
Driving Toward Precision Medicine for Acute Leukemias: Are We There Yet? 38
28654205 2017
27
Clinical and experimental efficacy of gemtuzumab ozogamicin in core binding factor acute myeloid leukemia. 38
29071049 2017
28
Minimal residual disease eradication with epigenetic therapy in core binding factor acute myeloid leukemia. 38
28494506 2017
29
Outcome after intensive reinduction therapy and allogeneic stem cell transplant in paediatric relapsed acute myeloid leukaemia. 38
28439893 2017
30
D816V mutation in the KIT gene activation loop has greater cell-proliferative and anti-apoptotic ability than N822K mutation in core-binding factor acute myeloid leukemia. 38
28506695 2017
31
Mutations in the CCND1 and CCND2 genes are frequent events in adult patients with t(8;21)(q22;q22) acute myeloid leukemia. 38
27843138 2017
32
Idarubicin Dose Escalation During Consolidation Therapy for Adult Acute Myeloid Leukemia. 38
28368672 2017
33
Prognostic Importance of C-KIT Mutations in Core Binding Factor Acute Myeloid Leukemia: A Systematic Review. 38
27613372 2017
34
Frontline treatment of acute myeloid leukemia in adults. 38
28109402 2017
35
Genetic abnormalities in core binding factor acute myeloid leukemia. 38
28883285 2017
36
Next-generation sequencing with a myeloid gene panel in core-binding factor AML showed KIT activation loop and TET2 mutations predictive of outcome. 38
27391574 2016
37
Comparison of Multiparameter Flow Cytometry Immunophenotypic Analysis and Quantitative RT-PCR for the Detection of Minimal Residual Disease of Core Binding Factor Acute Myeloid Leukemia. 38
27298396 2016
38
RNA-sequencing analysis of core binding factor AML identifies recurrent ZBTB7A mutations and defines RUNX1-CBFA2T3 fusion signature. 38
26968532 2016
39
Comprehensive mutational profiling of core binding factor acute myeloid leukemia. 38
26980726 2016
40
Stem Cell Modeling of Core Binding Factor Acute Myeloid Leukemia. 38
26880987 2016
41
Prognostic Significance of KIT Mutations in Core-Binding Factor Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis. 38
26771376 2016
42
Significance of KIT exon 17 mutation depends on mutant level rather than positivity in core-binding factor acute myeloid leukemia. 38
26771813 2016
43
Additional chromosomal abnormalities in core-binding factor acute myeloid leukemia. 38
26681050 2015
44
Antileukemic Activity of 2-Deoxy-d-Glucose through Inhibition of N-Linked Glycosylation in Acute Myeloid Leukemia with FLT3-ITD or c-KIT Mutations. 38
26206337 2015
45
Mass Cytometric Functional Profiling of Acute Myeloid Leukemia Defines Cell-Cycle and Immunophenotypic Properties That Correlate with Known Responses to Therapy. 38
26091827 2015
46
The activation loop tyrosine 823 is essential for the transforming capacity of the c-Kit oncogenic mutant D816V. 38
25435369 2015
47
Prognostic impact of residual normal metaphases in acute myeloid leukemia with t(8;21)(q22;q22). 38
26040504 2015
48
Core Binding Factor Acute Myeloid Leukemia: New Prognostic Categories and Therapeutic Opportunities. 38
26111469 2015
49
Dasatinib in high-risk core binding factor acute myeloid leukemia in first complete remission: a French Acute Myeloid Leukemia Intergroup trial. 38
25715404 2015
50
Complex karyotype, older age, and reduced first-line dose intensity determine poor survival in core binding factor acute myeloid leukemia patients with long-term follow-up. 38
25753065 2015

Variations for Core Binding Factor Acute Myeloid Leukemia

Expression for Core Binding Factor Acute Myeloid Leukemia

Search GEO for disease gene expression data for Core Binding Factor Acute Myeloid Leukemia.

Pathways for Core Binding Factor Acute Myeloid Leukemia

Pathways related to Core Binding Factor Acute Myeloid Leukemia according to GeneCards Suite gene sharing:

(show top 50) (show all 99)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.05 NRAS MVP KRAS KIT JAK2 HRAS
2
Show member pathways
13.88 NRAS KRAS KIT JAK2 HRAS FLT3
3
Show member pathways
13.69 NRAS KRAS KIT JAK2 HRAS FLT3
4
Show member pathways
13.56 NRAS KRAS KIT JAK2 HRAS FLT3
5
Show member pathways
13.32 NRAS KRAS KIT JAK2 HRAS CSF3
6
Show member pathways
13.32 NRAS KRAS KIT JAK2 HRAS FLT3
7
Show member pathways
13.26 NRAS KRAS KIT JAK2 HRAS FLT3
8
Show member pathways
13.23 TLE1 NRAS KRAS KIT HRAS FLT3
9
Show member pathways
13.08 NRAS KRAS KIT JAK2 HRAS CSF1R
10
Show member pathways
12.95 NRAS KRAS KIT JAK2 HRAS CBL
11
Show member pathways
12.93 NRAS KRAS JAK2 HRAS CBL
12
Show member pathways
12.84 NRAS KRAS KIT JAK2 HRAS FLT3
13
Show member pathways
12.83 NRAS KRAS JAK2 HRAS CBL
14
Show member pathways
12.76 NRAS KRAS KIT HRAS CBL
15 12.75 NRAS KRAS KIT HRAS FLT3 CSF1R
16
Show member pathways
12.73 NRAS KRAS JAK2 HRAS CBL
17
Show member pathways
12.71 NRAS KRAS KIT HRAS FLT3 CSF1R
18
Show member pathways
12.61 NRAS KRAS JAK2 HRAS
19
Show member pathways
12.61 NRAS KRAS HRAS CBL
20
Show member pathways
12.61 NRAS KRAS HRAS CBL
21
Show member pathways
12.6 NRAS KRAS HRAS CBL
22
Show member pathways
12.59 NRAS KRAS HRAS CBL
23 12.59 RUNX1 KIT JAK2 CEBPA CBL
24
Show member pathways
12.54 NRAS KRAS HRAS CBL
25
Show member pathways
12.5 NRAS KRAS HRAS CBL
26
Show member pathways
12.5 NRAS KRAS JAK2 HRAS CBL
27
Show member pathways
12.46 NRAS KRAS HRAS FLT3 CBL
28
Show member pathways
12.45 NRAS KRAS HRAS CBL
29
Show member pathways
12.44 NRAS KRAS KIT HRAS
30
Show member pathways
12.43 JAK2 HRAS CEBPA CBL
31
Show member pathways
12.43 NRAS KRAS HRAS CBL
32
Show member pathways
12.36 NRAS KRAS HRAS CBL
33
Show member pathways
12.35 RUNX1 NRAS KRAS KIT HRAS FLT3
34 12.34 NRAS KRAS HRAS CBL
35
Show member pathways
12.33 NRAS KRAS JAK2 HRAS
36
Show member pathways
12.32 NRAS KRAS JAK2 HRAS CSF3 CSF1R
37
Show member pathways
12.31 NRAS KRAS HRAS CBL
38
Show member pathways
12.27 NRAS KRAS KIT HRAS FLT3 CSF1R
39
Show member pathways
12.24 NRAS KRAS JAK2 HRAS CBL
40
Show member pathways
12.23 NRAS KRAS HRAS CSF1R
41 12.22 KRAS JAK2 HRAS CBL
42
Show member pathways
12.21 KIT JAK2 HRAS CBL
43
Show member pathways
12.18 NRAS KRAS JAK2 HRAS FLT3 CBL
44 12.17 NRAS KRAS HRAS CSF1R
45
Show member pathways
12.17 NRAS KRAS HRAS CBL
46 12.13 NRAS KRAS JAK2 HRAS
47
Show member pathways
12.11 NRAS KRAS JAK2 HRAS CBL
48
Show member pathways
12.11 NRAS KRAS JAK2 HRAS
49
Show member pathways
12.1 KRAS JAK2 HRAS CBL
50
Show member pathways
12.08 NRAS KRAS JAK2 HRAS

GO Terms for Core Binding Factor Acute Myeloid Leukemia

Cellular components related to Core Binding Factor Acute Myeloid Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 receptor complex GO:0043235 9.13 KIT FLT3 CSF1R
2 core-binding factor complex GO:0016513 8.62 RUNX1 CBFB

Biological processes related to Core Binding Factor Acute Myeloid Leukemia according to GeneCards Suite gene sharing:

(show all 41)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of cell proliferation GO:0008285 9.97 WT1 JAK2 HRAS CSF1R CEBPA
2 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.92 KIT HRAS FLT3 CSF1R
3 positive regulation of cell migration GO:0030335 9.92 KIT JAK2 HRAS CSF1R
4 positive regulation of gene expression GO:0010628 9.91 WT1 TLE1 RUNX2 KRAS KIT HRAS
5 positive regulation of DNA-binding transcription factor activity GO:0051091 9.85 KIT JAK2 CSF3
6 peptidyl-tyrosine phosphorylation GO:0018108 9.85 KIT JAK2 FLT3 CSF1R
7 male gonad development GO:0008584 9.84 WT1 KIT CBL
8 protein autophosphorylation GO:0046777 9.84 KIT JAK2 FLT3 CSF1R
9 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.83 KIT FLT3 CSF1R
10 negative regulation of apoptotic process GO:0043066 9.82 WT1 CSF1R CBL
11 MAPK cascade GO:0000165 9.8 NRAS KRAS KIT JAK2 HRAS FLT3
12 Ras protein signal transduction GO:0007265 9.78 NRAS KRAS HRAS
13 stimulatory C-type lectin receptor signaling pathway GO:0002223 9.77 NRAS KRAS HRAS
14 positive regulation of MAPK cascade GO:0043410 9.76 KIT HRAS FLT3 CSF1R
15 cellular response to cytokine stimulus GO:0071345 9.73 FLT3 CSF3 CSF1R
16 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.71 KIT JAK2 FLT3 CSF1R
17 positive regulation of actin cytoskeleton reorganization GO:2000251 9.68 HRAS CSF3
18 macrophage differentiation GO:0030225 9.68 CSF1R CEBPA
19 regulation of regulatory T cell differentiation GO:0045589 9.68 RUNX1 CBFB
20 regulation of keratinocyte differentiation GO:0045616 9.67 RUNX1 CBFB
21 regulation of intracellular estrogen receptor signaling pathway GO:0033146 9.67 RUNX1 CBFB
22 interleukin-6-mediated signaling pathway GO:0070102 9.67 JAK2 CBL
23 positive regulation of MAP kinase activity GO:0043406 9.67 KRAS KIT HRAS FLT3
24 mast cell degranulation GO:0043303 9.66 KIT CBL
25 regulation of bicellular tight junction assembly GO:2000810 9.65 RUNX1 CBFB
26 positive regulation of phospholipase C activity GO:0010863 9.65 KIT HRAS
27 cell maturation GO:0048469 9.65 RUNX2 CEBPA CBFB
28 hemopoiesis GO:0030097 9.65 RUNX2 RUNX1 KIT FLT3 CSF1R
29 regulation of myeloid cell differentiation GO:0045637 9.64 RUNX1 CBFB
30 regulation of B cell receptor signaling pathway GO:0050855 9.63 RUNX1 CBFB
31 granulocyte differentiation GO:0030851 9.63 CSF3 CEBPA
32 regulation of cytokine-mediated signaling pathway GO:0001959 9.61 RUNX1 CBFB
33 response to isolation stress GO:0035900 9.58 KRAS HRAS
34 myeloid progenitor cell differentiation GO:0002318 9.57 KIT FLT3
35 positive regulation of cell proliferation GO:0008284 9.56 RUNX2 KRAS KIT JAK2 HRAS FLT3
36 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.55 KIT JAK2 FLT3 CSF3 CBL
37 positive regulation of CD8-positive, alpha-beta T cell differentiation GO:0043378 9.51 RUNX1 CBFB
38 negative regulation of CD4-positive, alpha-beta T cell differentiation GO:0043371 9.49 RUNX1 CBFB
39 cytokine-mediated signaling pathway GO:0019221 9.23 KRAS KIT JAK2 FLT3 CSF3 CSF1R
40 signal transduction GO:0007165 10.19 TLE1 NRAS KRAS KIT JAK2 HRAS
41 positive regulation of transcription by RNA polymerase II GO:0045944 10.07 WT1 RUNX2 RUNX1 HRAS CSF3 CEBPA

Molecular functions related to Core Binding Factor Acute Myeloid Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 ATP binding GO:0005524 9.95 RUNX2 RUNX1 KIT JAK2 FLT3 CSF1R
2 protein binding GO:0005515 9.86 WT1 TLE1 RUNX2 RUNX1 NRAS MVP
3 DNA-binding transcription factor activity GO:0003700 9.77 WT1 RUNX2 RUNX1 CEBPA CBFB
4 transcription regulatory region DNA binding GO:0044212 9.62 WT1 RUNX2 RUNX1 CEBPA
5 protein tyrosine kinase activity GO:0004713 9.46 KIT JAK2 FLT3 CSF1R
6 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.43 KIT FLT3 CSF1R
7 nucleotide binding GO:0000166 9.1 NRAS KRAS KIT JAK2 HRAS FLT3

Sources for Core Binding Factor Acute Myeloid Leukemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....